The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Open accessAbstract
Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the treatment of human cancer. Based on positive preclinical and clinical studies, bortezomib was subsequently approved for the clinical use as a front-line treatment for newly diagnosed multiple myeloma patients and for the treatment of relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this drug has become the staple of treatment. The approval of bortezomib by the US Food and Drug Administration (FDA) represented a significant milestone as the first proteasome inhibitor to be implemented in the treatment of malignant disease. Bortezomib has shown a positive clinical benefit either alone or as a part of combination therapy to induce chemo-/radio-sensitization or overcome drug resistance. One of the major mechanisms of bortezomib associated with its anticancer activity is through upregulation of NOXA, which is a proapoptotic protein, and NOXA may interact with the anti-apoptotic proteins of Bcl-2 subfamily Bcl-X(L) and Bcl-2, and result in apoptotic cell death in malignant cells. Another important mechanism of bortezomib is through suppression of the NF-κB signaling pathway resulting in the down-regulation of its anti-apoptotic target genes. Although the majority of success achieved with bortezomib has been in hematological malignancies, its effect toward solid tumors has been less than encouraging. Additionally, the widespread clinical use of bortezomib continues to be hampered by the appearance of dose-limiting toxicities, drug-resistance and interference by some natural compounds. These findings could help guide physicians in refining the clinical use of bortezomib, and encourage basic scientists to generate next generation proteasome inhibitors that broaden the spectrum of efficacy and produce a more durable clinical response in cancer patients. Other desirable applications for the use of proteasome inhibitors include the development of inhibitors against specific E3 ligases, which act at an early step in the ubiquitin-proteasome pathway, and the discovery of less toxic and novel proteasome inhibitors from natural products and traditional medicines, which may provide more viable drug candidates for cancer chemoprevention and the treatment of cancer patients in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ali, S., Ahmad, A., Banerjee, S., Padhye, S., Dominiak, K., Schaffert, J. M., Wang, Z., Philip, P. A., & Sarkar, F. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4598 · Cited by 424
RetractedHershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
The Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
STRUCTURE AND FUNCTIONS OF THE 20S AND 26S PROTEASOMES
Coux, O., Tanaka, K., & Goldberg, A. L. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.004101 · Cited by 2,487
Structure of 20S proteasome from yeast at 2.4Å resolution
Groll, M., Ditzel, L., Löwe, J., Stock, D., Bochtler, M., Bartunik, H. D., & Huber, R. (1997) · Nature · doi:10.1038/386463a0 · Cited by 2,257
Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Protein degradation and protection against misfolded or damaged proteins.
Goldberg, A. L. (2003) · Nature · doi:10.1038/nature02263 · Cited by 2,088
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., & Rolfe, M. (1995) · Science · doi:10.1126/science.7624798 · Cited by 1,817
The ubiquitin-proteasome proteolytic pathway
Ciechanover, A. (1994) · Cell · doi:10.1016/0092-8674(94)90396-4 · Cited by 1,791
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
The Proteasome: Paradigm of a Self-Compartmentalizing Protease
Baumeister, W., Walz, J., Zühl, F., & Seemüller, E. (1998) · Cell · doi:10.1016/s0092-8674(00)80929-0 · Cited by 1,494
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
The ubiquitin-proteasome pathway: on protein death and cell life
Ciechanover, A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7151 · Cited by 1,426
The IKK NF-κB system: a treasure trove for drug development
Karin, M., Yamamoto, Y., & Wang, Q. M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1279 · Cited by 1,364
The proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
Ubiquitin signalling in the NF-κB pathway
Chen, Z. J. (2005) · Nature Cell Biology · doi:10.1038/ncb0805-758 · Cited by 1,184
Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentinc, M., Draetta, G. F., Jessup, J. M., & Pagano, M. (1997) · Nature Medicine · doi:10.1038/nm0297-231 · Cited by 1,031
Ubiquitin, proteasomes, and the regulation of intracellular protein degradation
Hochstrasser, M. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80031-x · Cited by 874
Ubiquitin-mediated proteolysis: biological regulation via destruction
Ciechanover, A., Orian, A., & Schwartz, A. L. (2000) · BioEssays · doi:10.1002/(sici)1521-1878(200005)22:5<442::aid-bies6>3.0.co;2-q · Cited by 853
The development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
The ubiquitin-proteasome system
Nandi, D., Tahiliani, P., Kumar, A., & Chandu, D. (2006) · Journal of Biosciences · doi:10.1007/bf02705243 · Cited by 758
Diehl, J. A., Zindy, F., & Sherr, C. J. (1997) · Genes & Development · doi:10.1101/gad.11.8.957 · Cited by 746
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P. G., Niesvizky, R., Alexanian, R., Limentani, S. A., Alsina, M., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05188.x · Cited by 740
Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
Chen, D., Cui, Q. C., Yang, H., & Dou, Q. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2126 · Cited by 674
Self-citationOrlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hajek, R., Spencer, A., San Miguel, J., Robak, T., Dmoszynska, A., Horvath, N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5460 · Cited by 645
Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy
Kane, R. C., Bross, P. F., Farrell, A. T., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-6-508 · Cited by 628
Yang, H., Chen, D., Cui, Q. C., Yuan, X., & Dou, Q. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4529 · Cited by 586
Self-citationThe proteasome: structure, function, and role in the cell
ADAMS, J. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00081-1 · Cited by 585
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Orlowski, R. Z., & Kuhn, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2218 · Cited by 578
O'Connor, O. A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.050 · Cited by 577
The proteasome: a novel target for cancer chemotherapy
Almond, J., & Cohen, G. (2002) · Leukemia · doi:10.1038/sj.leu.2402417 · Cited by 538
The Proteasome, a Novel Protease Regulated by Multiple Mechanisms
DeMartino, G. N., & Slaughter, C. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22123 · Cited by 530
Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J. E., Hagemeister, F., Fayad, L., Dang, N. H., Samaniego, F., Wang, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.108 · Cited by 526
Ester Bond-containing Tea Polyphenols Potently Inhibit Proteasome Activity in Vitro and in Vivo
Nam, S., Smith, D. M., & Dou, Q. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004209200 · Cited by 504
Sunwoo, J. B., Chen, Z., Dong, G., Yeh, N. T., Bancroft, C. C., Sausville, E. A., Adams, J., Elliott, P. J., & Waes, C. V. (2001) · PubMed · Cited by 473
Oerlemans, R., Franke, N. E., Assaraf, Y. G., Cloos, J., van Zantwijk, I., Berkers, C. R., Scheffer, G. L., Debipersad, K., Vojtekova, K., Lemos, C., et al. (2008) · Blood · doi:10.1182/blood-2007-08-104950 · Cited by 454
LeBlanc, R., Catley, L. P., Hideshima, T., Lentzsch, S., Mitsiades, C. S., Mitsiades, N., Neuberg, D. S., Goloubeva, O. G., Pien, C. S., Adams, J., et al. (2002) · PubMed · Cited by 450
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Aghajanian, C. A., Soignet, S. L., Dizon, D. S., Pien, C. S., Adams, J., Elliott, P. J., Sabbatini, P. J., Miller, V. A., Hensley, M. L., Pezzulli, S., et al. (2002) · PubMed · Cited by 447
Li, B., & Dou, Q. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.070047997 · Cited by 446
Papandreou, C. N., Daliani, D. D., Nix, D., Yang, H., Madden, T., Wang, X., Pien, C. S., Millikan, R. E., Tu, S.-M., Pagliaro, L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.106 · Cited by 434
Mateos, M.-V., Richardson, P. G., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0638 · Cited by 433
Fribley, A., Zeng, Q., & Wang, C.-Y. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.22.9695-9704.2004 · Cited by 424
Ma, M. H., Yang, H. H., Parker, K., Manyak, S. J., Friedman, J. M., Altamirano, C. V., Wu, Z.-Q., Borad, M. J., Frantzen, M., Roussos, E., et al. (2003) · PubMed · Cited by 414
Jagannath, S., Durie, B. G. M., Wolf, J., Camacho, E., Irwin, D., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schenkein, D., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05540.x · Cited by 398
The role of the ubiquitin-proteasome pathway in apoptosis
Orlowski, R. Z. (1999) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400505 · Cited by 386
Pei, X.-Y., Dai, Y., & Grant, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0561 · Cited by 382
Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N. C., Richardson, P. G., Carrasco, R. D., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199604 · Cited by 363
Won, K. A., & Reed, S. I. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00793.x · Cited by 360
Goldberg, A. L., Cascio, P., Saric, T., & Rock, K. L. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00098-6 · Cited by 345
Kane, R. C., Farrell, A. T., Sridhara, R., & Pazdur, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0170 · Cited by 341
Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells
Qin, J.-Z., Ziffra, J., Stennett, L., Bodner, B., Bonish, B. K., Chaturvedi, V., Bennett, F., Pollock, P. M., Trent, J. M., Hendrix, M. J. C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0676 · Cited by 336
Bortezomib for the Treatment of Mantle Cell Lymphoma
Kane, R. C., Dagher, R., Farrell, A., Ko, C.-W., Sridhara, R., Justice, R., & Pazdur, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0871 · Cited by 332
Orlowski, R. Z., Voorhees, P. M., Garcia, R. A., Hall, M. D., Kudrik, F. J., Allred, T., Johri, A. R., Jones, P. E., Ivanova, A., Van Deventer, H. W., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2911 · Cited by 319
Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB
Russo, S. M., Tepper, J. E., Baldwin, A. S., Liu, R., Adams, J., Elliott, P., & Cusack, J. C. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01446-8 · Cited by 318
Oakervee, H. E., Popat, R., Curry, N., Smith, P., Morris, C., Drake, M., Agrawal, S., Stec, J., Schenkein, D., Esseltine, D., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05519.x · Cited by 317
Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells
Chen, D., Daniel, K. G., Chen, M. S., Kuhn, D. J., Landis-Piwowar, K. R., & Dou, Q. P. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.02.022 · Cited by 306
Self-citationRichardson, P. G., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07573.x · Cited by 305
Abnormally high expression of proteasomes in human leukemic cells.
Kumatori, A., Tanaka, K., Inamura, N., Sone, S., Ogura, T., Matsumoto, T., Tachikawa, T., Shin, S., & Ichihara, A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7071 · Cited by 304
Groll, M., Heinemeyer, W., Jäger, S., Ullrich, T., Bochtler, M., Wolf, D. H., & Huber, R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.10976 · Cited by 300
O'Connor, O. A., Stewart, A. K., Vallone, M., Molineaux, C. J., Kunkel, L. A., Gerecitano, J. F., & Orlowski, R. Z. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0822 · Cited by 295
Richardson, P. G., Hideshima, T., & Anderson, K. C. (2003) · Cancer Control · doi:10.1177/107327480301000502 · Cited by 292
Discovery and development of the anticancer agent salinosporamide A (NPI-0052)
Fenical, W., Jensen, P. R., Palladino, M. A., Lam, K. S., Lloyd, G. K., & Potts, B. C. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.075 · Cited by 291
Golden, E. B., Lam, P. Y., Kardosh, A., Gaffney, K. J., Cadenas, E., Louie, S. G., Petasis, N. A., Chen, T. C., & Schönthal, A. H. (2009) · Blood · doi:10.1182/blood-2008-07-171389 · Cited by 289
Orlowski, R. Z., Eswara, J. R., Lafond-Walker, A., Grever, M. R., Orłowski, M., & Dang, C. V. (1998) · PubMed · Cited by 275
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
Shah, S. A., Potter, M. W., McDade, T. P., Ricciardi, R., Perugini, R. A., Elliott, P. J., Adams, J., & Callery, M. P. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1150 · Cited by 260
Structural Features of the 26 S Proteasome Complex
Peters, J.-M., Cejka, Z., Harris, J. R., Kleinschmidt, J. A., & Baumeister, W. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1646 · Cited by 250
Arlt, A., Bauer, I., Schafmayer, C., Tepel, J., Müerköster, S. S., Brosch, M., Röder, C., Kalthoff, H., Hampe, J., Moyer, M. P., et al. (2009) · Oncogene · doi:10.1038/onc.2009.264 · Cited by 244
Curcumin Inhibits the Proteasome Activity in Human Colon Cancer Cells In vitro and In vivo
Milacic, V., Banerjee, S., Landis-Piwowar, K. R., Sarkar, F. H., Majumdar, A. P. N., & Dou, Q. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6246 · Cited by 243
Landis-Piwowar, K. R., Huo, C., Chen, D., Milacic, V., Shi, G., Chan, T. H., & Dou, Q. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4699 · Cited by 236
Self-citationFrankel, A., Man, S., Elliott, P. J., Adams, J., & Kerbel, R. S. (2000) · PubMed · Cited by 232
Inhibition of Proteasomal Function by Curcumin Induces Apoptosis through Mitochondrial Pathway
Jana, N. R., Dikshit, P., Goswami, A., & Nukina, N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310369200 · Cited by 232
Fernández, Y., Verhaegen, M., Miller, T. P., Rush, J. L., Steiner, P., Opipari, A. W., Lowe, S. W., & Soengas, M. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0686 · Cited by 222
Berenson, J. R., Yang, H. H., Sadler, K., Jarutirasarn, S. G., Vescio, R. A., Mapes, R., Purner, M., Lee, S.-P., Wilson, J., Morrison, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2383 · Cited by 210
Landowski, T. H., Megli, C. J., Nullmeyer, K. D., Lynch, R. M., & Dorr, R. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3684 · Cited by 202
Role of NF-κB in the Rescue of Multiple Myeloma Cells From Glucocorticoid-Induced Apoptosis by Bcl-2
Feinman, R., Koury, J., Thames, M., Barlogie, B., Epstein, J., & Siegel, D. S. (1999) · Blood · doi:10.1182/blood.v93.9.3044 · Cited by 201
Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma
Kondagunta, G. V., Drucker, B., Schwartz, L., Bacik, J., Marion, S., Russo, P., Mazumdar, M., & Motzer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.155 · Cited by 192
Kalejta, R. F., & Shenk, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0538058100 · Cited by 191
Ovaa, H., Kessler, B. M., Rolén, U., Galardy, P. J., Ploegh, H. L., & Masucci, M. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308411100 · Cited by 190
Tea polyphenols, their biological effects and potential molecular targets.
Chen, D., Milacic, V., Chen, M. S., Wan, S. B., Lam, W. H., Huo, C., Landis‐Piwowar, K. R., Cui, Q. C., Wali, A., Chan, T. H., et al. (2008) · PubMed · doi:10.14670/hh-23.487 · Cited by 185
Self-citationTumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition
Nikiforov, M. A., Riblett, M., Tang, W.-H., Gratchouck, V., Zhuang, D., Fernandez, Y., Verhaegen, M., Varambally, S., Chinnaiyan, A. M., Jakubowiak, A. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708380104 · Cited by 173
P53: An ubiquitous target of anticancer drugs
Blagosklonny, M. V. (2001) · International Journal of Cancer · doi:10.1002/ijc.10158 · Cited by 170
Nawrocki, S. T., Bruns, C. J., Harbison, M. T., Bold, R. J., Sweeney‐Gotsch, B., Abbruzzese, J. L., Elliott, P. J., Adams, J., & McConkey, D. J. (2002) · PubMed · Cited by 170
Kazi, A., Daniel, K. G., Smith, D. M., Kumar, N. B., & Dou, Q. P. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00414-3 · Cited by 168
Comparative Selectivity and Specificity of the Proteasome Inhibitors BzLLLCOCHO, PS-341, and MG-132
Crawford, L., Walker, B., Ovaa, H., Chauhan, D., Anderson, K. C., Morris, T. C. M., & Irvine, A. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0605 · Cited by 164
Marine Antitumor Drugs: Status, Shortfalls and Strategies
Bhatnagar, I., & Kim, S. (2010) · Marine Drugs · doi:10.3390/md8102702 · Cited by 164
The proteasome as a potential target for novel anticancer drugs and chemosensitizers
Landis‐Piwowar, K. R., Milacic, V., Chen, D., Yang, H., Zhao, Y., Chan, T. H., Yan, B., & Dou, Q. P. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.11.001 · Cited by 163
Self-citationBelch, A. R., Kouroukis, C. T., Crump, M., Sehn, L. H., Gascoyne, R. D., Klasa, R. J., Powers, J., Wright, J. R., & Eisenhauer, E. A. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl316 · Cited by 162
Bortezomib: A Review of its Use in Patients with Multiple Myeloma
Curran, M. P., & McKeage, K. (2009) · Drugs · doi:10.2165/00003495-200969070-00006 · Cited by 161
Bazzaro, M., Lee, M. K., Zoso, A., Stirling, W. L. H., Santillan, A., Shih, I., & Roden, R. B. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2321 · Cited by 160
Proteasome inhibitors as potential novel anticancer agents
Dou, Q. P., & Li, B. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0095 · Cited by 158
Fanucchi, M. P., Fossella, F. V., Belt, R., Natale, R., Fidias, P., Carbone, D. P., Govindan, R., Raez, L. E., Robert, F., Ribeiro, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1853 · Cited by 158
Orlowski, R. Z., & Dees, E. C. (2002) · Breast Cancer Research · doi:10.1186/bcr460 · Cited by 150
Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer
Adams, J. (2002) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(02)00343-5 · Cited by 150
Padhyé, S., Banerjee, S., Chavan, D., Pandye, S., Swamy, K. V., Ali, S. S., Li, J., Dou, Q. P., & Sarkar, F. H. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9955-6 · Cited by 147
A phase II study of bortezomib in the treatment of metastatic malignant melanoma
Markovic, S. N., Geyer, S. M., Dawkins, F. W., Sharfman, W., Albertini, M. R., Maples, W. J., Fracasso, P. M., Fitch, T. R., LoRusso, P. M., Adjei, A. A., et al. (2005) · Cancer · doi:10.1002/cncr.21108 · Cited by 143
A novel proteasome inhibitor NPI-0052 as an anticancer therapy
Chauhan, D., Hideshima, T., & Anderson, K. C. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603406 · Cited by 141
Yang, C. H., Gonzalez-Angulo, A. M., Reuben, J. M., Booser, D. J., Pusztai, L., Krishnamurthy, S., Esseltine, D. L., Stec, J. J., Broglio, K. R., Islam, R., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj131 · Cited by 141
Shah, M. H., Young, D., Kindler, H. L., Webb, I. J., Kleiber, B., Wright, J., & Grever, M. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0422 · Cited by 139
Chen, D., & Dou, Q. P. (2010) · Current Protein and Peptide Science · doi:10.2174/138920310791824057 · Cited by 135
Self-citationBerenson, J. R., Matous, J., Swift, R. A., Mapes, R., Morrison, B., & Yeh, H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1812 · Cited by 132
Chen, D., Landis‐Piwowar, K. R., Chen, M. S., & Dou, Q. P. (2007) · Breast Cancer Research · doi:10.1186/bcr1797 · Cited by 125
Self-citationThe role of nuclear factor-?b in the biology and treatment of multiple myeloma
Berenson, J. R., Ma, H. M., & Vescio, R. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90036-3 · Cited by 124
Padhyé, S., Yang, H., Jamadar, A., Cui, Q. C., Chavan, D., Dominiak, K., McKinney, J., Banerjee, S., Dou, Q. P., & Sarkar, F. H. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9900-8 · Cited by 122
Terpos, E., Kastritis, E., Ρούσσου, Μ., Heath, D., Christoulas, D., Anagnostopoulos, N. I., Eleftherakis-Papaiakovou, E., Tsionos, K., Croucher, P. I., & Dimopoulos, M. A. (2008) · Leukemia · doi:10.1038/leu.2008.235 · Cited by 121
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
Caravita, T., de Fabritiis, P., Palumbo, A., Amadori, S., & Boccadoro, M. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0555 · Cited by 120
Mikhael, J. R., Belch, A. R., Prince, H. M., Lucio, M. N., Maiolino, Â., Corso, A., Petrucci, M. T., Musto, P., Komarnicki, M. A., & Stewart, A. K. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07409.x · Cited by 116
RAINA, P. N., & RAMAKRISHNAN, C. V. (1964) · PubMed · Cited by 115
Strauss, S. J., Higginbottom, K., Jueliger, S., Maharaj, L., Allen, P. D., Schenkein, D. P., Lister, T. A., & Joel, S. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3254 · Cited by 111
Ascorbic acid inhibits antitumor activity of bortezomib in vivo
Perrone, G., Hideshima, T., Ikeda, H., Okawa, Y., Calabrese, E., Gorgun, G., Santo, L., Cirstea, D., Raje, N., Chauhan, D., et al. (2009) · Leukemia · doi:10.1038/leu.2009.83 · Cited by 109
Lü, S., Yang, J., Song, X., Gong, S., Zhou, H., Guo, L., Song, N., Bao, X., Chen, P., & Wang, J. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.138131 · Cited by 109
Hoyt, M. A., & Coffino, P. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4133-9 · Cited by 106
Hamilton, A. L., Eder, J. P., Pavlick, A. C., Clark, J. W., Liebes, L., García‐Carbonero, R., Chachoua, A., Ryan, D. P., Soma, V., Farrell, K., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.136 · Cited by 103
Reece, D. E., Rodriguez, G. P., Chen, C. I., Trudel, S., Kukreti, V., Mikhael, J. R., Pantoja, M. A., Xu, W., & Stewart, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2372 · Cited by 103
Soligo, D., Servida, F., Delia, D., Fontanella, E., Lamorte, G., Caneva, L., Fumiatti, R., & Deliliers, G. L. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02683.x · Cited by 102
Enhanced Killing of Melanoma Cells by Simultaneously Targeting Mcl-1 and NOXA
Qin, J., Xin, H., Sitailo, L. A., Denning, M. F., & Nickoloff, B. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0747 · Cited by 100
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib
Liu, F., Agrawal, S. G., Movasaghi, Z., Wyatt, P. B., Rehman, I. U., Gribben, J. G., Newland, A. C., & Jia, L. (2008) · Blood · doi:10.1182/blood-2008-04-150227 · Cited by 97
Lü, S., Chen, Z., Yang, J., Chen, L., Gong, S., Zhou, H., Guo, L., & Wang, J. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.04.013 · Cited by 94
Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target
Jia, L., Yang, J., Hao, X., Zheng, M., He, H., Xiong, X., Xu, L., & Sun, Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1592 · Cited by 92
Lü, S., Yang, J., Chen, Z., Gong, S., Zhou, H., Xu, X., & Wang, J. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.04.001 · Cited by 88
The proteasome: a novel target for anticancer therapy
Montagut, C. O., Rovira, A., & Albanell, J. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0176-8 · Cited by 87
Clinical development of novel proteasome inhibitors for cancer treatment
Yang, H., Zonder, J. A., & Dou, Q. P. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903002074 · Cited by 85
Self-citationKong, X., Alvarez‐Castelao, B., Lin, Z., Castaño, J. G., & Caro, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700704200 · Cited by 84
Engel, R. H., Brown, J. A., Roenn, J. H. V., O'Regan, R. M., Bergan, R. C., Badve, S., RADEMAKER, A. W., & Gradishar, W. J. (2007) · Cancer Investigation · doi:10.1080/07357900701506573 · Cited by 83
Sun, J., Nam, S., Lee, C., Li, B., Coppola, D., Hamilton, A. D., Dou, Q. P., & Sebti, S. M. (2001) · PubMed · Cited by 82
Proteasomes in apoptosis: villains or guardians?
W�jcik, C. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050483 · Cited by 82
Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications
Chauhan, D., & Anderson, K. C. (2003) · APOPTOSIS · doi:10.1023/a:1024164700094 · Cited by 77
Dreicer, R., Petrylak, D. P., Agus, D. B., Webb, I. J., & Roth, B. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2046 · Cited by 75
Potts, B. C. M., & Lam, K. S. (2010) · Marine Drugs · doi:10.3390/md8040835 · Cited by 73
Molecular Pathways That Modify Tumor Radiation Response
Pervan, M., Pajonk, F., Sun, J.-R., Withers, H. R., & McBride, W. H. (2001) · American Journal of Clinical Oncology · doi:10.1097/00000421-200110000-00013 · Cited by 73
Cell cycle regulatory E3 ubiquitin ligases as anticancer targets
Pray, T. R., Parlati, F., Huang, J., Wong, B. R., Payan, D. G., Bennett, M. K., Issakani, S. D., Molineaux, S. M., & Demo, S. D. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00121-8 · Cited by 72
Lioni, M., Noma, K., Snyder, A. R., Klein–Szanto, A. J., Diehl, J. A., Rustgi, A. K., Herlyn, M., & Smalley, K. S. M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0391 · Cited by 69
Singh, A., Palladino, M. A., Lloyd, K. G., Potts, B. C. M., Chauhan, D., & Anderson, K. C. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08144.x · Cited by 67
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors
Ryan, D. P., O’Neil, B. H., Supko, J. G., Lima, C. M. R., Dees, E. C., Appleman, L. J., Clark, J. W., Fidias, P., Orlowski, R. Z., Kashala, O., et al. (2006) · Cancer · doi:10.1002/cncr.22280 · Cited by 67
Multiple Myeloma: New Insights and Therapeutic Approaches
Anderson, K. C., Kyle, M. R. A., Dalton, W. S., Landowski, T., Shain, K., Jove, R., Hazlehurst, L., & Berenson, J. (2000) · Hematology · doi:10.1182/asheducation-2000.1.147 · Cited by 67
Bortezomib (millennium pharmaceuticals).
Dou, Q. P., & Goldfarb, R. H. (2002) · PubMed · Cited by 66
Chen, W., Lee, J., Cho, S. Y., & Fine, H. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3906 · Cited by 65
Scagliotti, G. V., Germonpré, P. R., Bosquée, L., Vansteenkiste, J., Gervais, R., Planchard, D., Reck, M., de Marinis, F., Lee, J. S., Park, K., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.07.011 · Cited by 58
Bortezomib: A novel chemotherapeutic agent for hematologic malignancies
Utecht, K. N., & Kolesar, J. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070272 · Cited by 52
Voortman, J., Smit, E. F., Honeywell, R. J., Kuenen, B. C., Peters, G. J., de Velde, H. J. V., & Giaccone, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0061 · Cited by 50
Hainsworth, J. D., Meluch, A. A., Spigel, D. R., Barton, J., Simons, L., Meng, C., Gould, B., & Greco, F. A. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.004 · Cited by 49
Popat, R., Oakervee, H. E., Williams, C. D., Cook, M. A., Craddock, C., Basu, S., Singer, C. R. J., Harding, S. J., Foot, N. J., Hallam, S. L., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07572.x · Cited by 46
A Phase II Trial of Bortezomib and Prednisone for Castration Resistant Metastatic Prostate Cancer
Morris, M. J., Kelly, W. K., Slovin, S. F., Ryan, C. J., Eicher, C., Heller, G., & Scher, H. I. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.08.015 · Cited by 45
Kim, T. Y., Park, J., Oh, B., Min, H. J., Jeong, T., Lee, J. H., Suh, C., Cheong, J., Kim, H. J., Yoon, S., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07752.x · Cited by 38
The Ubiquitin Proteasome Pathway from Bench to Bedside
Orlowski, R. Z. (2005) · Hematology · doi:10.1182/asheducation-2005.1.220 · Cited by 37
Kukreja, A., Hutchinson, A., Mazumder, A., Vesole, D. H., Angitapalli, R., Jagannath, S., O’Connor, O. A., & Dhodapkar, M. V. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06369.x · Cited by 36
Bortezomib In Mantle Cell Lymphoma
Suh, K. S., & Goy, A. H. (2008) · Future Oncology · doi:10.2217/14796694.4.2.149 · Cited by 31
Gordon, M. S. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79128-0 · Cited by 25
Edelman, M. J. (2005) · Clinical Lung Cancer · doi:10.3816/clc.2005.s.011 · Cited by 21
Fonseca, R., & Rajkumar, S. V. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.046 · Cited by 16
Cited by
NF‐κB and the link between inflammation and cancer
DiDonato, J. A., Mercurio, F., & Karin, M. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01099.x · Cited by 1,482
Deubiquitylating enzymes and drug discovery: emerging opportunities
Harrigan, J. A., Jacq, X., Martin, N. M., & Jackson, S. P. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.152 · Cited by 940
Inflammatory bone loss: pathogenesis and therapeutic intervention
Redlich, K., & Smolen, J. S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3669 · Cited by 830
Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics
Vangijzegem, T., Stanicki, D., & Laurent, S. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1554647 · Cited by 548
Cancer Treatment Using Peptides: Current Therapies and Future Prospects
Thundimadathil, J. (2012) · Journal of Amino Acids · doi:10.1155/2012/967347 · Cited by 491
Metadata
- Authors
- Chen, D., Frezza, M., Schmitt, S., Kanwar, J., & P. Dou, Q.
- Venue
- Current Cancer Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-03-01
- Volume
- 11
- Issue
- 3
- Pages
- 239-253
- ISSN
- 1568-0096 (ISSN-L)
- OpenAlex
- W2099395323
- Cited by
- 795
- References
- 159
- FWCI
- 17.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.